FLT3 and acute myeloid leukemia: The incorporation of PTKi into the standard of care has caused a paradigm shift in the treatment of CML (PTKi: ABL1 and SRC inhibitors), CLL (PTKi: BTK inhibitors), Ph+ B-ALL (PTKi: ABL1 and SRC inhibitors), and AML with FLT3 mutations (PTKi: FLT3 inhibitors)[29,30].